Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T22:18:43.592Z.
Calculation as of: 2026-10-06T22:18:43.592Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 77ffd79d43f0055242b38282a97f53e69ef3ec7586b4a3f7de15a7f16befe37a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
SpyGlass Pharma, Inc. Common Stock
Market Cap
$828.48M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$833.81M
Price/OCF Ratio
N/A
TTM Avg
10.75
3Y Avg
10.75
5Y Avg
10.75
Market Cap
$838.62M
Price/OCF Ratio
N/A
TTM Avg
185.06
3Y Avg
185.06
5Y Avg
185.06
Market Cap
$853.13M
Price/OCF Ratio
10.75
TTM Avg
9.59
3Y Avg
13.93
5Y Avg
222.48
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| SpyGlass Pharma, Inc. Common Stock (SGP) | $828.48M | N/A | N/A | N/A | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $833.81M | N/A | 10.75 | 10.75 | 10.75 |
| Beta Bionics, Inc. (BBNX)vs › | $838.16M | N/A | N/A | N/A | N/A |
| Pacific Biosciences of California, Inc. (PACB)vs › | $838.62M | N/A | 185.06 | 185.06 | 185.06 |
| Ardelyx, Inc. (ARDX)vs › | $817.67M | N/A | 5.49 | 6.61 | 6.61 |
| Jade Biosciences, Inc. (JBIO)vs › | $816.13M | N/A | N/A | N/A | N/A |
| SL Science Holding Ltd (SLBT)vs › | $852.35M | N/A | N/A | N/A | N/A |
| InMode Ltd. (INMD)vs › | $804.16M | 9.08 | 9.81 | 9.87 | 15.02 |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $853.13M | 10.75 | 9.59 | 13.93 | 222.48 |
| Alumis Inc. (ALMS)vs › | $855.38M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
